ReCode Therapeutics Presents Preclinical Data Using SORT-LNP™ and RNA Platforms to Rescue CFTR Function at the 44th European Cystic Fibrosis Conference (ECFS)
These data showcase the potential of our differentiated RNA-based molecular therapies to treat cystic fibrosis.
- These data showcase the potential of our differentiated RNA-based molecular therapies to treat cystic fibrosis.
- By leveraging our LNP platform to deliver genomic medicines, we have demonstrated the ability to restore cystic fibrosis transmembrane conductance regulator (CFTR) function through both tRNA and mRNA approaches, said David Lockhart, Ph.D., CEO & President, ReCode Therapeutics.
- RCT223 was shown to restore CFTR function for at least 72 hours in patient-derived hBE cells after a single administration.
- The Companys pipeline includes lead programs for patients with life-limiting genetic respiratory diseases, including cystic fibrosis and primary ciliary dyskinesia.